In 2010, the National Psoriasis Foundation Medical Board (21) only recommended the cautious use of anti-TNF-α inhibitors in closely monitored patients with HIV and very refractory psoriasis or debilitating psoriatic arthritis. The gene discussed is TNF; the disease is psoriasis.